Clin2
NCT07748039Likely a fitNot yet recruiting

Comparing two clot-busting drugs before clot removal for acute stroke

Acute Ischemic StrokeLarge Vessel OcclusionAnterior Circulation Brain Infarction

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial compares two clot-dissolving medications (tenecteplase and reteplase) given before a procedure to remove a large clot from a brain artery. It aims to see which drug works better for people who have had an acute ischemic stroke and are eligible for both treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,440 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have had an acute ischemic stroke, which is a type of stroke caused by a blocked blood vessel in the brain.
  • You are within 4.5 hours of when your stroke symptoms started.
  • Imaging tests (like a CT or MRI) show a large clot in a major brain artery (the carotid or middle cerebral artery).
  • You are at least 18 years old.
  • You have not had any bleeding in the brain (intracranial hemorrhage) based on initial scans.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07253181Recruiting· Phase 3
Stroke clot-busting drug before transfer for artery clearing

This trial tests whether giving a clot-busting drug (tenecteplase) before transferring you to a hospital that can do a procedure to remove the clot improves outcomes for people who had a stroke up to 24 hours earlier. You may qualify if you have a blockage in a large artery in the front of your brain and can still get the procedure.

Beijing, Beijing Municipality
NCT07519889Not yet recruiting
Safety comparison of two clot-busting drugs for acute stroke

This study compares the safety of two FDA-approved clot-dissolving medicines (rhTNK-tPA and rt-PA) given through an IV to patients having an acute ischemic stroke (a stroke caused by a blood clot in the brain). Researchers want to understand which treatment is safer and how well each works.

NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07201688Recruiting· Phase 3
Extending the window for stroke clot-busting drug

This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.

Puyang, Henan
NCT07168278Not yet recruiting· Phase 3
Tenecteplase vs standard care for large vessel stroke 4.5-24 hours

This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.

Hefei, Anhui
NCT07389460Not yet recruiting· Phase 3
Study of a clot-busting drug before thrombectomy for stroke

This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.

Lanzhou, Gansu

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.